Drug Trial Radar · NCT02245620
A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly
Last checked: Nov 20, 2026Latest source record: Jun 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Jan 15, 2015
Primary completion
Jul 6, 2016
Study completion Jul 6, 2016
Sponsor
- Lead sponsor
- Stealth BioTherapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 2, randomized, double-blind, placebo-controlled study, enrolling 41 elderly subjects with previous evidence of mitochondrial dysfunction to evaluate whether the administration of MTP-131 (elamipretide) will change either hand skeletal muscle energetics or muscle performance in age-related skeletal muscle mitochondrial dysfunction.
Conditions
- Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Interventions
ElamipretideDrug
Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
PlaceboDrug
Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in ATPmax (Maximal ATP Synthetic Rate)Time frame: From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Washington Medical Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.